Syndax Announces Participation at Two Upcoming Investor Conferences
WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:
Related news for (SNDX)
- Today’s Top Performers: MoBot’s Market Review 08/05/25 09:00 AM
- MoBot alert highlights: NASDAQ: MLGO, NASDAQ: SNDX, NASDAQ: LTBR, NASDAQ: INEO, NASDAQ: PDSB (05/22/25 07:00 PM)
- Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)